Chinese  	Chinese  	 JJ	O
subgroup  	subgroup  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
global  	global  	 JJ	O
anticoagulant  	anticoagulant  	 JJ	B-NP
registry  	registry  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
FIELD  	FIELD  	 NNP	O
( 	( 	 -LRB-	O
GARFIELD 	GARFIELD 	 NNP	B-NP
)  	)  	 -RRB-	O
registry  	registry  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
non-valvular  	non-valvular  	 JJ	B-NP
atrial  	atrial  	 JJ	I-NP
fibrillation  	fibrillation  	 NN	I-NP
To  	To  	 TO	O
describe  	describe  	 VB	O
the  	the  	 DT	O
baseline  	baseline  	 NN	B-NP
characteristics  	characteristics  	 NNS	I-NP
and  	and  	 CC	O
antithrombotic  	antithrombotic  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
non-valvular  	non-valvular  	 JJ	B-NP
atrial  	atrial  	 JJ	I-NP
fibrillation  	fibrillation  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
Chinese  	Chinese  	 JJ	O
subgroup  	subgroup  	 NN	B-NP
of  	of  	 IN	I-NP
GRAFIELD 	GRAFIELD 	 NNP	I-NP
.  	.  	 .	O
GARFIELD  	GARFIELD  	 NNP	B-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
observational  	observational  	 JJ	B-NP
registry  	registry  	 JJ	I-NP
study  	study  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
newly  	newly  	 RB	O
diagnosed  	diagnosed  	 VBN	B-NP
non-valvular  	non-valvular  	 JJ	I-NP
atrial  	atrial  	 JJ	I-NP
fibrillation 	fibrillation 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
805  	805  	 CD	O
adult  	adult  	 NN	B-NP
(  	(  	 -LRB-	O
≥18  	≥18  	 CD	O
years  	years  	 NNS	O
old 	old 	 JJ	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
mean  	mean  	 JJ	O
age 	age 	 NN	O
:  	:  	 :	O
( 	( 	 -LRB-	O
66.6  	66.6  	 CD	O
±  	±  	 CD	O
11.4 	11.4 	 CD	O
)  	)  	 -RRB-	O
years  	years  	 NNS	O
old 	old 	 JJ	O
,  	,  	 ,	O
39.4 	39.4 	 CD	O
%  	%  	 NN	O
female  	female  	 NN	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
317 	317 	 CD	O
) 	) 	 -RRB-	O
)  	)  	 -RRB-	O
diagnosed  	diagnosed  	 VBD	O
with  	with  	 IN	O
non-valvular  	non-valvular  	 JJ	B-NP
atrial  	atrial  	 JJ	I-NP
fibrillation  	fibrillation  	 NN	I-NP
within  	within  	 IN	O
the  	the  	 DT	O
previous  	previous  	 JJ	O
6  	6  	 CD	O
weeks  	weeks  	 NNS	O
were  	were  	 VBD	O
recruited  	recruited  	 VBN	O
between  	between  	 IN	O
December  	December  	 NNP	O
2009  	2009  	 CD	O
and  	and  	 CC	O
October  	October  	 NNP	O
2011  	2011  	 CD	O
at  	at  	 IN	O
29  	29  	 CD	O
hospitals  	hospitals  	 NNS	O
from  	from  	 IN	O
China 	China 	 NNP	O
.  	.  	 .	O
Baseline  	Baseline  	 JJ	B-NP
data  	data  	 NNS	I-NP
included  	included  	 VBD	I-NP
demographics 	demographics 	 NNS	I-NP
,  	,  	 ,	O
medical  	medical  	 JJ	B-NP
history 	history 	 NN	I-NP
,  	,  	 ,	O
nature  	nature  	 NN	O
of  	of  	 IN	O
atrial  	atrial  	 JJ	B-NP
fibrillation 	fibrillation 	 NN	I-NP
,  	,  	 ,	O
CHA 	CHA 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
DS 	DS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
)  	)  	 -RRB-	I-NP
score 	score 	 NN	I-NP
,  	,  	 ,	O
CHA 	CHA 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
DS 	DS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
-VASc  	-VASc  	 JJ	I-NP
score 	score 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
treatment  	treatment  	 NN	O
at  	at  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	O
of  	of  	 IN	O
diagnosis 	diagnosis 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
216  	216  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
26.8 	26.8 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
age  	age  	 NN	O
above  	above  	 IN	O
75  	75  	 CD	O
years  	years  	 NNS	O
old 	old 	 JJ	O
,  	,  	 ,	O
116  	116  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
14.4 	14.4 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
had  	had  	 VBD	O
history  	history  	 NN	O
of  	of  	 IN	O
stroke  	stroke  	 NN	O
or  	or  	 CC	O
TIA 	TIA 	 NNP	B-NP
,  	,  	 ,	O
261  	261  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
32.4 	32.4 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
had  	had  	 VBD	O
coronary  	coronary  	 JJ	B-NP
artery  	artery  	 NN	I-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
Mean  	Mean  	 NNP	B-NP
CHADS 	CHADS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
)  	)  	 -RRB-	I-NP
score  	score  	 NN	I-NP
was  	was  	 VBD	O
1.7  	1.7  	 CD	O
±  	±  	 CD	O
1.1 	1.1 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
391  	391  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
48.5 	48.5 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
had  	had  	 VBD	O
a  	a  	 DT	O
CHADS 	CHADS 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
)  	)  	 -RRB-	I-NP
score  	score  	 VBP	O
≥  	≥  	 CD	O
2 	2 	 CD	O
.  	.  	 .	O
Mean  	Mean  	 NNP	B-NP
CHA 	CHA 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
DS 	DS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
-VASc  	-VASc  	 JJ	I-NP
score  	score  	 NN	I-NP
was  	was  	 VBD	O
2.9  	2.9  	 CD	O
±  	±  	 CD	O
1.7 	1.7 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
630  	630  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
78.3 	78.3 	 NNP	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
had  	had  	 VBD	O
a  	a  	 DT	O
CHA 	CHA 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
DS 	DS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
-VASc  	-VASc  	 JJ	I-NP
score  	score  	 NN	I-NP
≥  	≥  	 CD	O
2.Overall 	2.Overall 	 CD	O
,  	,  	 ,	O
159  	159  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
19.8 	19.8 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
received  	received  	 VBD	O
no  	no  	 DT	O
anticoagulant  	anticoagulant  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
,  	,  	 ,	O
51.6 	51.6 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
415 	415 	 CD	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
received  	received  	 VBD	O
aspirin  	aspirin  	 JJ	O
and  	and  	 CC	O
only  	only  	 RB	O
28.7 	28.7 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
231 	231 	 CD	O
)  	)  	 -RRB-	O
patients  	patients  	 NNS	O
received  	received  	 VBD	O
either  	either  	 DT	O
warfarin  	warfarin  	 NN	B-NP
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
179 	179 	 CD	O
,  	,  	 ,	O
22.2 	22.2 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
new  	new  	 JJ	B-NP
oral  	oral  	 JJ	I-NP
anticoagulants  	anticoagulants  	 NNS	I-NP
( 	( 	 -LRB-	O
NOAC 	NOAC 	 NNP	B-NP
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
52 	52 	 CD	O
,  	,  	 ,	O
6.5 	6.5 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Among  	Among  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
CHADS2  	CHADS2  	 CD	B-NP
score  	score  	 CD	I-NP
≥  	≥  	 CD	O
2  	2  	 CD	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
391 	391 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
68.3 	68.3 	 CD	O
%  	%  	 NN	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
267 	267 	 CD	O
)  	)  	 -RRB-	O
did  	did  	 VBD	O
not  	not  	 RB	O
receive  	receive  	 VB	O
anticoagulant  	anticoagulant  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Among  	Among  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
CHA 	CHA 	 NNP	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
DS 	DS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
-VASc  	-VASc  	 JJ	I-NP
≥  	≥  	 CD	O
2  	2  	 CD	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
630 	630 	 CD	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
71.7 	71.7 	 CD	O
%  	%  	 NN	O
( 	( 	 -LRB-	O
n  	n  	 CD	O
=  	=  	 SYM	O
452 	452 	 CD	O
)  	)  	 -RRB-	O
did  	did  	 VBD	O
not  	not  	 RB	O
receive  	receive  	 VB	O
anticoagulant  	anticoagulant  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
very  	very  	 RB	O
high  	high  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
stroke 	stroke 	 NN	O
,  	,  	 ,	O
i.e.  	i.e.  	 FW	O
CHA 	CHA 	 FW	B-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
DS 	DS 	 NNP	I-NP
( 	( 	 -LRB-	I-NP
2 	2 	 LS	I-NP
) 	) 	 -RRB-	I-NP
-VASc  	-VASc  	 JJ	I-NP
≥  	≥  	 CD	O
6 	6 	 CD	O
,  	,  	 ,	O
the  	the  	 DT	O
proportion  	proportion  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
received  	received  	 VBD	B-NP
NOAC  	NOAC  	 NNP	I-NP
and  	and  	 CC	O
warfarin  	warfarin  	 NNS	B-NP
were  	were  	 VBD	O
identical  	identical  	 JJ	O
( 	( 	 -LRB-	O
14.9 	14.9 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
7 	7 	 CD	O
/ 	/ 	 CD	O
47 	47 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
contemporary  	contemporary  	 JJ	B-NP
observational  	observational  	 JJ	I-NP
registry  	registry  	 JJ	I-NP
study  	study  	 NN	I-NP
shows  	shows  	 NNS	I-NP
that  	that  	 IN	O
the  	the  	 DT	O
anticoagulant  	anticoagulant  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
is  	is  	 VBZ	O
somehow  	somehow  	 RB	O
improved  	improved  	 VBN	O
but  	but  	 CC	O
still  	still  	 RB	O
underused  	underused  	 VBN	O
in  	in  	 IN	O
Chinese  	Chinese  	 NNP	O
NVAF  	NVAF  	 NNP	B-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
Stroke  	Stroke  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
according  	according  	 VBG	O
to  	to  	 TO	O
risk  	risk  	 VB	O
scores  	scores  	 NNS	O
and  	and  	 CC	O
current  	current  	 JJ	O
guidelines  	guidelines  	 NNS	O
in  	in  	 IN	O
these  	these  	 DT	O
patients  	patients  	 NNS	O
remains  	remains  	 VBZ	O
an  	an  	 DT	O
important  	important  	 JJ	O
task  	task  	 NN	O
in  	in  	 IN	O
China 	China 	 NNP	O
.  	.  	 .	O
